CYP2D6 genotype determination in the Danish population
- 1 October 1994
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 47 (3) , 221-225
- https://doi.org/10.1007/bf02570501
Abstract
CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, D6-wt. However, the D6-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the D6-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11–4.10) and the corresponding value in heterozygous EM was 0.36 (0.11–9.10). The median difference was 0.09 (95% confidence interval: 0.02–0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring.Keywords
This publication has 26 references indexed in Scilit:
- Debrisoquine oxidation polymorphismPharmacogenetics, 1993
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and NomenclatureDNA and Cell Biology, 1993
- Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancerPharmacogenetics, 1992
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Extremely Slow Metabolism of Amitriptyline but Normal Metabolism of Imipramine and Desipramine in an Extensive Metabolizer of Sparteine, Debrisoquine, and MephenytoinTherapeutic Drug Monitoring, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22Genomics, 1988
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984